PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Kenyan Pharmaceutical Industry Can Expect Significant Growth Despite Global Conditions Finds Frost & Sullivan - Expanding therapeutic areas are creating significant opportunities for growth within the Kenyan pharmaceutical industry
Kenyan Pharmaceutical Industry Can Expect Significant Growth Despite Global Conditions Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Cape Town, South Africa, 2009/04/06 - Expanding therapeutic areas are creating significant opportunities for growth within the Kenyan pharmaceutical industry.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Although infectious diseases are still responsible for the largest burden of disease in Kenya, non-communicable diseases are becoming a major problem, with the incidence of type II diabetes, cardiovascular disease and cancer increasing rapidly.

New analysis from Frost & Sullivan (pharma.frost.com), Strategic Analysis of the Pharmaceutical Industry in Kenya, finds that the market earned $208.6 million in 2007 and estimates this to reach $557.8 million in 2014. The analysis covered generic pharmaceuticals, branded pharmaceuticals, anti-diabetic pharmaceuticals, oncology pharmaceuticals, cardiovascular pharmaceuticals and anti-infective pharmaceuticals.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Patrick Cairns, Corporate Communications, at patrick.cairns[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by email.

"The prevalence of diabetes is reported to be between 6 and 10 per cent, and an estimated 3.5 million people suffer from diabetes in Kenya," notes Frost & Sullivan Research Analyst Jolize Gerber. "The number of diagnosed cases in 2007 was over two million, of which approximately 1.8 million were reported to be type II diabetics. The anti-diabetic pharmaceutical market in Kenya earned revenues of $18.0 million in 2007 and is estimated to reach $ 29.0 million in 2014."

This heightened prevalence of type II diabetes is due to rapid changes in culture, an aging population, increasing urbanisation, dietary changes and the rise of sedentary lifestyles.

The Kenyan Ministry of Health is currently developing a comprehensive control programme for diabetes. Part of this treatment programme consists of raising awareness on the symptoms of diabetes and mobilising the population to visit diabetes clinics. This would ultimately improve the ratio of diagnosed cases, fuelling the growth of anti-diabetic treatments.

"Thirty nine main clinics and 113 mini clinics have been set up by the DMI and MoH in recent years," says Gerber. "However, there remains a pressing need to provide good quality but affordable anti-diabetic medication to these clinics as well as to private hospitals."

A key restraint in this market is however the prevailing poverty and illiteracy in Kenya. The population also has limited access to health facilities. This has led to 42.6 per cent of diabetic cases being undiagnosed, and hence, left untreated, causing these patients to develop secondary complications.

"The lack of stringent control measures has also led to the continued presence of counterfeit and substandard medications in the Kenyan market," states Frost & Sullivan Research Analyst Jolize Gerber. "However, stricter enforcement of regulations, growth of the generic pharmaceuticals market and expansion of public treatment programmes will fuel future growth of the pharmaceutical industry."

Strategic Analysis of the Pharmaceutical Industry in Kenya is part of the Pharmaceuticals & Biotechnology Growth Partnership Service programme, which also includes research in the following markets: Strategic Analysis of the Healthcare Industry in Kenya, Strategic Analysis of Oncology Services in Key Sub-Saharan African Countries, Infectious Disease Pharmaceutical Markets in key Sub-Saharan African countries and Strategic Analysis of the Healthcare Industry in Tanzania. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents.

Strategic Analysis of the Pharmaceutical Industry in Kenya / M34B

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Kenyan Pharmaceutical Industry Can Expect Significant Growth Despite Global Conditions Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)